Luke Evnin Sells 47,963 Shares of Werewolf Therapeutics (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 47,963 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $0.72, for a total value of $34,533.36. Following the completion of the sale, the director owned 1,679,330 shares of the company’s stock, valued at $1,209,117.60. The trade was a 2.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Luke Evnin also recently made the following trade(s):

• On Friday, May 1st, Luke Evnin sold 58,394 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.73, for a total value of $42,627.62.
• On Thursday, April 30th, Luke Evnin sold 168,262 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.72, for a total value of $121,148.64.
• On Wednesday, April 29th, Luke Evnin sold 56,559 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.69, for a total value of $39,025.71.
• On Tuesday, April 28th, Luke Evnin sold 95,412 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.73, for a total value of $69,650.76.
• On Monday, April 27th, Luke Evnin sold 53,940 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.85, for a total value of $45,849.00.

Werewolf Therapeutics Stock Performance

NASDAQ:HOWL traded down $0.03 during mid-day trading on Monday, reaching $0.69. The stock had a trading volume of 199,935 shares, compared to its average volume of 410,071. The firm has a 50 day moving average price of $0.81 and a two-hundred day moving average price of $0.88. The stock has a market capitalization of $33.53 million, a P/E ratio of -0.51 and a beta of 0.41. Werewolf Therapeutics, Inc. has a one year low of $0.53 and a one year high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last released its earnings results on Friday, March 27th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.34) by $0.14. Research analysts forecast that Werewolf Therapeutics, Inc. will post -1.29 earnings per share for the current year.

Analyst Upgrades and Downgrades

HOWL has been the subject of several recent research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Monday, April 20th. Wall Street Zen upgraded Werewolf Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, April 7th. Two equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $3.75.

Institutional Trading of Werewolf Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HOWL. Regal Investment Advisors LLC boosted its holdings in Werewolf Therapeutics by 93.3% in the fourth quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company’s stock valued at $33,000 after acquiring an additional 25,389 shares in the last quarter. Vontobel Holding Ltd. raised its holdings in Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company’s stock worth $38,000 after purchasing an additional 24,003 shares in the last quarter. Qube Research & Technologies Ltd bought a new position in Werewolf Therapeutics in the 2nd quarter worth $48,000. AQR Capital Management LLC purchased a new stake in shares of Werewolf Therapeutics in the 1st quarter worth about $79,000. Finally, Bridgeway Capital Management LLC lifted its position in shares of Werewolf Therapeutics by 157.7% in the 2nd quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company’s stock worth $111,000 after purchasing an additional 62,414 shares during the period. Hedge funds and other institutional investors own 64.84% of the company’s stock.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.